Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection
Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection
复制标题
Galectin-1 过度表达与人肝细胞癌切除后不良预后相关
DOI：
10.1111/j.1440-1746.2012.07130.x
复制
发表时间：
2012-08-01
影响因子：
4.1
通讯作者：
Qiu, Shuang-Jian
中科院分区：
文献类型：
--
作者：
Wu, Han;Chen, Pei;Qiu, Shuang-Jian
背景与目的：半乳糖凝集素-1的高表达预示着一些肿瘤患者预后不良。本研究的目的是探讨其在肝细胞癌（HCC）切除术后的预后价值。方法：采用组织微阵列技术对386例HCC患者的半凝集素-1和肿瘤浸润性FoxP3+调节性T细胞（Tregs）进行验证，并对其与患者临床表现和预后的相关性进行统计学评估。结果：我们发现半乳糖凝集素-1在HCC中普遍上调，与肿瘤侵袭性特征（如血管侵袭、包被不完全、分化差、多发、肿瘤大小大）显著相关。半凝集素-1高表达患者的肿瘤复发（P = 0.025）和总生存期（P = 0.021）明显低于低表达患者。即使在早期疾病中，高半乳糖凝集素-1表达也与缩短生存期（P < 0.001）和增加肿瘤复发率（P = 0.005）独立相关。多因素Cox比例风险分析显示，半乳糖凝集素-1是预测HCC预后不良的独立指标。半凝集素-1水平与浸润肿瘤的FoxP3+ Tregs数量呈正相关（r = 0.416, P < 0.001），两者联合可作为较好的预后指标。galectin-1high组和FoxP3high组HCC患者术后肿瘤复发率和生存率显著低于其他组（P均< 0.001）。结论：半乳糖凝集素-1可能是肝癌切除术后新的预后因素，可能是一个优先考虑的治疗靶点。
Background and Aim: The high expression of the galectin-1 predicts poor patient outcome in several tumors. The aim of this study was to investigate its prognostic value in patients with hepatocellular carcinoma (HCC) after resection. Methods: Galectin-1 and tumor-infiltrating FoxP3+ regulatory T cells (Tregs) were validated by tissue microarrays from HCC patients (n = 386) and statistically assessed for correlations with the clinical profiles and the prognosis of the patients. Results: We found that galectin-1, which was prevalently upregulated in HCC, was significantly associated with tumor invasive characteristics (such as vascular invasion, incomplete encapsulation, poor differentiation, multiple number, and large tumor size). Patients with high galectin-1 expression had a significantly poorer tumor recurrence (P = 0.025) and overall survival (P = 0.021) than those with low galectin-1 expression. Even in early-stage disease, high galectin-1 expression was also independently associated with shortened survival (P < 0.001) and increased tumor recurrence (P = 0.005). Multivariate Cox proportional hazards analysis showed that galectin-1 was an independent marker for predicting the poor prognosis of HCC. The galectin-1 level was positively related to the number of tumor-infiltrating FoxP3+ Tregs (r = 0.416, P < 0.001), and their combination served as a better prognosticator. The postoperative tumor recurrence and survival of HCC patients with galectin-1high and FoxP3high were significantly poorer than the other groups (both P < 0.001). Conclusions: Galectin-1 might be a new prognostic factor for HCC after resection and could potentially be a high-priority therapeutic target.